Rationale Experimental evidence suggests that the differential behavioral effects of benzodiazepines depend on their relative actions at γ-aminobutyric acid type A (GABA A ) receptors that contain either an α1, α2, α3, or α5 subunit. Objectives The present study was aimed at understanding the role of α3 subunit-containing GABA A (α3GABA A ) receptors by examining the behavioral pharmacology of TP003 (4,2′-difluoro-5′-[8-fluoro-7-(1-hydroxy-1-methylethyl)imidazo [1,2-a]pyridine-3-yl]biphenyl-2-carbonitrile), which shows functional selectivity for α3GABA A receptors. Methods First, a conflict procedure was used to assess the anxiolytic-like effects of TP003 and a representative clinically available benzodiazepine. TP003 was also administered before daily periods of sucrose pellet availability to evaluate potential hyperphagic effects. In separate experiments, observable behavioral effects were used to assess the motor and sedative effects of TP003. Results Administration of TP003 produced robust anticonflict effects without the rate-decreasing effects that were observed with the representative benzodiazepine. Unlike the reported effects of benzodiazepines, TP003 did not enhance palatable food consumption. However, increases in observable sleep-associated posture were induced by TP003, as were decreases in some species-typical behaviors (vocalization, locomotion, and environment-directed behaviors). When evaluated for its ability to induce a procumbent posture, TP003 failed to produce an effect. Conclusions Based on conflict and observation tests in monkeys, our results suggest that TP003 may have anxiolytic properties but lack ataxic, hyperphagic, and pronounced sedative effects characteristic of classical benzodiazepines. TP003 did induce myorelaxant-like effects and had relatively mild sedative effects. Collectively, these results suggest that α3GABA A receptors play an important role in the anxiolytic-like and motor effects of benzodiazepine-type drugs.
Introduction
The γ-aminobutyric acid type A (GABA A ) receptors are the primary sites of action for benzodiazepines and related drugs used to treat anxiety and sleep disorders. The therapeutic use of benzodiazepine-type drugs for the treatment of these disorders is constrained, however, by the occurrence of other characteristic effects that are mediated through GABA A receptors. In addition to their therapeutic effects, benzodiazepines produce unwanted side effects including daytime drowsiness, impairment of motor coordination, and increases in food consumption.
Benzodiazepine-type drugs act by binding allosterically to a distinct site on GABA A receptors which produces changes that enhance the ability of GABA to increase chloride conductance. Research during the past two decades has revealed the existence of multiple subtypes of the GABA A receptor (e.g., Pritchett et al. 1989; Rudolph et al. 2001) . Subsequent reports have postulated that the diverse behavioral effects of benzodiazepine-type drugs may reflect actions at different subtypes of GABA A receptors (Rudolph et al. 1999; McKernan et al. 2000; Löw et al. 2000; Rowlett et al. 2005) .
The GABA A receptors in the central nervous system are pentamers constituted from structurally distinct proteins, with each protein family consisting of different subunits (for a review, see Rudolph et al. 2001 ). The majority of GABA A receptors are composed of α, β, and γ subunits and benzodiazepines bind to a site on the native GABA A receptor that is located at the interface of the γ2 subunit and one of the α1, α2, α3, or α5 subunits. Benzodiazepines do not bind to the corresponding α4-and α6-subunitcontaining receptors. Approximately 75% of the GABA A receptors in the brain contain α1, α2, and α3 subunits (McKernan and Whiting, 1996) , and GABA A receptors containing α1 subunits (α1GABA A receptors) have been recently implicated in the sedative effects of benzodiazepines, whereas GABA A receptors containing α2 and α3 subunits (α2GABA A and α3GABA A receptors) are associated with the anxiolytic and myorelaxant effects of benzodiazepines (McKernan et al. 2000; Löw et al. 2000; Rowlett et al. 2005 , Morris et al. 2006 . GABA A receptors containing α5 subunits (α5GABA A receptors), in contrast, are a relatively minor population in the brain as a whole but are preferentially expressed within the hippocampus and play a role in certain memory processes but are not responsible for the anxiolytic or motor effects associated with benzodiazepines (Collinson et al. 2002; Crestani et al. 2002; Atack et al. 2006 ; but see Savić et al. 2008) .
Pharmacological efforts to attribute the contribution of GABA A receptor subtypes to the multiple effects of benzodiazepines have been enhanced in recent years by the increasing availability of compounds with selectivity for the individual receptor subtypes. In this regard, Dias et al. (2005) described an imidazopyridine compound, TP003, which exhibits "functional selectivity" rather than binding selectivity for GABA A receptor subtypes containing α3 subunits. That is, in vitro TP003 has comparatively high agonist efficacy at α3GABA A receptors but essentially no efficacy at α1GABA A , α2GABA A , and α5GABA A receptors (Dias et al. 2005) . Because TP003 exhibits appreciable efficacy only at α3GABA A receptors, the extent to which this compound induces an effect characteristic of conventional benzodiazepines can be interpreted as evidence for a specific role of α3GABA A receptors in that particular effect.
Using this approach in the present study, we evaluated the ability of TP003 to engender characteristic anxiolyticlike, hyperphagic, motor, and sedative effects in relevant non-human primate models of the therapeutic and side effects of benzodiazepines (Platt et al. 2002; Licata et al. 2005; Duke et al. 2006; Rowlett et al. 2006) . The anxiolytic-like effects of TP003 were first assessed in a conflict procedure in which behavior was maintained under a fixed-ratio (FR) schedule of food delivery in the absence (non-suppressed responding) and presence (suppressed responding) of response-contingent electric shock. In addition, hyperphagic effects were assessed by administering TP003 before 10-min periods of sucrose pellet availability. Finally, previously validated observational techniques were used to assess the motor and sedative effects of TP003. The behavioral effects of TP003 are discussed in relation to previous studies assessing both conventional benzodiazepines and subtype-selective GABA A receptor agonists.
Materials and methods

Animals
The subjects were adult rhesus monkeys (Macaca mulatta) for the conflict studies and adult squirrel monkeys (Saimiri sciureus) for the sucrose pellet consumption and observation studies. Separate groups of monkeys were used for each procedure. Monkeys in the conflict studies were maintained at 90-95% of their freefeeding weights; the other monkeys were not foodrestricted. Monkeys were housed individually and maintained on a 12-h lights-on/12-h lights-off cycle (lights on at 0600 h), with water being available continuously. All testing occurred during the lights-on phase of the cycle. Rhesus monkeys were prepared with a chronic indwelling venous catheter according to the procedures described by Platt et al. (2005) . The animals in this study were maintained in accordance with the "Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research" (National Research Council 2003) , and the principles of laboratory animal care were adhered to.
Conflict procedure Four rhesus monkeys (two males, two females) were trained as described in detail by . A daily session consisted of four cycles, each preceded by a 10-min time out period in which all lights in the chamber were off and responding had no programmed consequences. Each cycle consisted of two components. The first component was signaled by red stimulus lights and consisted of a FR 18 schedule of food pellet delivery (Bioserve, Frenchtown, NJ, USA) followed by a 10-s time out. The second component, signaled by green stimulus lights, consisted of the FR 18 schedule of food delivery combined with a FR 20 schedule of foot shock delivery (1.5-3.0 mA, adjusted for each monkey based on individual performance, 0.25-s duration). Both components were 5 min in duration or ended after the monkey obtained five food pellets or received three foot shocks, whichever occurred first.
Test sessions were conducted once or twice per week. Here, i.v. injections of vehicle or drug were administered in the fifth minute of each time out. In successive cycles, increasing doses of the test drug were administered using a cumulative dosing procedure. The dependent measure was the average rates of responding (responses/s), calculated by dividing responses by time during components 1 and 2, excluding responding during time outs or reinforcer delivery.
Sucrose pellet consumption Sucrose pellet consumption was evaluated as described in Duke et al. (2006) . Briefly, male squirrel monkeys (N=5) were placed in the observation area once a week with access to a dish containing 100 sucrose pellets (P.J. Noyes, Lancaster, NH, USA) for 10 min. Drugs or vehicle were administered intramuscularly (i.m.) 15 min prior to each test session. Sucrose pellet consumption was measured by subtracting the number of pellets remaining in the food dish or elsewhere in the observation chamber from 100.
Observation Five male squirrel monkeys were habituated to an observation arena and injection procedures (described in Platt et al. 2002) for approximately 1 month. Following habituation, 30-min observational sessions were conducted following a 15-min pretreatment of drug or vehicle. During the sixth, eighteenth, and thirtieth minute of each 30-min session, the monkeys were removed briefly from the observation arena by a trained handler and evaluated for ataxia, defined as the inability to balance on a stainless steel transport pole held in the horizontal plane. During each ataxia assessment, a score of 0 indicated that the monkey was able to balance normally on the transport pole, a score of 1 indicated inability to balance, and a score of 2 indicated that the monkey could neither balance nor support its weight on the pole. In addition, a measurement of muscle resistance was taken in order to determine myorelaxant effects (cf. Licata et al. 2009 ). After rating the ability of the monkey to balance on the pole, the experimenter then grasped one leg and gently extended it to assess the degree of resistance to flexion. A score of 0 indicated that the monkey retracted its leg normally, a score of −1 indicated delayed and/or reduced resistance to leg flexion, and a score of −2 indicated no flexion of the leg.
Scoring of videotapes was conducted by observers trained to use the behavioral scoring system described by Platt et al. (2002) . Eight behaviors (Platt et al. 2002) were scored by recording their presence or absence in 15-s intervals during three 5-min observation periods across the session (0-5 min, 12-17 min, 24-29 min). Frequency scores were calculated from these data as the proportion of 15-s intervals in which a particular behavior occurred, and the maximum possible score was 20.
Data analysis and drug preparation Effects of the doses of compounds were evaluated by conducting a priori Bonferroni t-tests (parametric data) or Dunn's Q statistic (nonparametric data), comparing individual doses to vehicle injection. Potency values (dose engendering 50% maximum effect, ED 50 ) were calculated in individual monkeys by loglinear regression analysis. For all comparisons, the alpha level was set at p≤0.05.
TP003 was provided by Merck, Sharp, & Dohme Research Laboratories (Harlow, UK) and was prepared in a vehicle of 10% benzyl alcohol, 50% propylene glycol, and 40% sterile water. Alprazolam was purchased from Tocris-Cookson (Ellisville, MO, USA) and was dissolved in 50% propylene glycol and 50% sterile water. Figure 1a shows the effects of TP003 on the fixedratio schedule of food pellet delivery (non-suppressed responding) and the conjoint schedule of food delivery and electric shock presentation (suppressed responding). Following vehicle administration, the rates of responding during both components were similar to those observed during training sessions (i.e., between 2.0 and 3.0 responses/s during the non-suppressed component and less than 0.1 responses/s during the suppressed component). TP003 increased the mean rates of suppressed responding compared to vehicle at doses of 1.0 to 5.6 mg/kg (Bonferroni t-tests, p<0.05) with an ED 50 value of 0.53 mg/kg, i.v. Across the doses tested, TP003 did not affect the response rates during the non-suppressed component.
Results
Conflict
We also determined the anti-conflict effects of alprazolam as a comparative standard. The administration of alprazolam engendered a characteristic increase in the rates of suppressed responding at low to intermediate doses and attenuated the rates of non-suppressed responding at higher doses (Fig. 1b) , and the ED 50 values from each component are included in Table 1 . As can be seen in the table, alprazolam was ∼45-fold more potent than TP003 and attenuated non-suppressed responding at doses approximately tenfold higher than those that increased the rates of suppressed responding. For comparison purposes, the previously reported potencies of HZ-166 and zolpidem, two subtype-selective drugs, are also shown in Table 1 .
Ataxia and myorelaxation The ataxic and myorelaxant effects of TP003 as assessed in the quantitative observational procedures are shown in Fig. 2 . The administration of vehicle did not engender the ataxic or myorelaxant effects in any monkey. TP003 also did not increase the ataxia scores across the dose range tested. However, dosedependent decreases in muscle resistance scores were observed after TP003 administration, with an effect significantly different from vehicle administration at 1.0 mg/kg (Dunn's Q, p<0.05). The median scores from the maximally effective dose of TP003 and, for comparison, the previously reported scores of alprazolam and zolpidem are shown in Table 2 .
Sucrose pellet consumption The hyperphagic effects of TP003, as determined in the assay of sucrose pellet consumption, are shown in Fig. 3a . Under baseline conditions, monkeys consumed a mean (± S.E.M.) of 19± 4 sucrose pellets during the 10-min access period. Sucrose pellet consumption was not altered following the administration of vehicle. Across the doses tested, TP003 also did not significantly affect the consumption of sucrose pellets. The percent increase in sucrose pellet consumption following administration of TP003 and, for Table 3 . Figure 3 also shows the observable behavioral effects of TP003 in squirrel monkeys. Dosedependent decreases in vocalization ( Fig. 3b ; minimum effective dose=0.3 mg/kg), locomotion ( Fig. 3c ; minimum effective dose = 1.0 mg/kg), and environment-directed behavior ( Fig. 3d ; minimum effective dose=0.1 mg/kg) were observed following the administration of TP003 (Bonferroni t-tests, p<0.05). The frequency measures of rest and procumbent posture induced by TP003 are also shown in Fig. 3 . TP003 dose-dependently increased the frequency of rest posture ( Fig. 3e ; minimum effective dose=1.0 mg/kg; Bonferroni t-tests, p<0.05). In contrast, increases in procumbent posture were not observed across the doses tested (Fig. 3f) . The mean frequency scores for passive visual and self-directed behaviors (a combination of scores for grooming and scratching) were not altered by TP003 across the dose range tested (0.1-1.0 mg/kg, data not shown). The behavioral frequency scores that were engendered by the maximally effective dose of TP003 and, for comparison, the previously reported scores of alprazolam and zolpidem are also shown in Table 3 .
Sedative-motor effects
Discussion
Conventional benzodiazepines bind non-selectively at GABA A receptors containing α1, α2, α3, and α5 subunits; however, the role of different GABA A receptor subtypes in the behavioral effects of these drugs has not been characterized fully. We now demonstrate that TP003, a novel ligand with functional selectivity at α3GABA A receptors, is effective in the behavioral measures of the anxiolytic and myorelaxant effects of benzodiazepines in monkeys. TP003 also engendered rest posture, reduced locomotion, and environment-directed behaviors-a profile of effects that raise the possibility of a role of α3GABA A receptors in relatively mild sedative effects induced by benzodiazepines. In contrast, TP003 was ineffective in the behavioral assays of the ataxic, hyperphagic, and more pronounced sedative effects (i.e., procumbent posture) of benzodiazepine-type drugs. Together these findings provide evidence that sets apart the profile of behavioral effects induced by selective α3GABA A receptor stimulation vs. the profile of behavioral effects engendered by conventional and other subtype-selective benzodiazepines.
Procedures that assess the effects of drugs on experimentally induced conflict are often used to assess the potential anxiolytic effects of these drugs in humans (Geller and Seifter 1962; Spealman 1979; Kleven and Koek 1999; Rowlett et al. 2006) . Previous studies from our laboratory have used a conflict procedure developed for rhesus monkeys to assess the anxiolytic effects of conventional benzodiazepines and other positive GABA A receptor modulators with either selective affinity or selective efficacy for GABA A receptor subtypes Rowlett et al. 2006; Fischer et al. 2010 ). The results from these studies provide evidence for a differential role of GABA A receptors in the anxiolytic effects of benzodiazepines. As an example, L-838,417, a compound with functional selectivity at α2GABA A , α3 GABA A , and α5 GABA A receptors, produced an anti-conflict effect similar to conventional non-selective benzodiazepines . A similar result was observed when XHe-II-053 and HZ-166, drugs with high intrinsic efficacy at α2GABA A and α3GABA A receptors, were assessed in the conflict procedure (Fischer et al. 2010) . Together with data suggesting that drugs selective for α1GABA A receptors (e.g., zolpidem) are only marginally effective in this procedure , these experiments support a key role for α2GABA A and α3GABA A receptors, but not α1GABA A receptors, in benzodiazepineinduced anxiolysis. Subsequent demonstrations of anxiolytic-like effects after the administration of the partial α2GABA A and α3GABA A receptor agonist TPA023 in other rodent and primate models of anxiety also support this hypothesis . In the present study, administration of TP003 produced an anti-conflict effect to the same degree as observed with the conventional benzodiazepine alprazolam (see also Rowlett et al. 2006) . These data provide clear evidence that a compound with selective efficacy at α3GABA A receptors can produce anxiolytic-like effects in primates and support a role for this receptor subtype in the anxiolytic effects of benzodiazepines. It is noteworthy that TP003 produced an anti-conflict effect without altering the rates of non-suppressed responding over the dose range tested. Similar results were observed when L-838,417 was assessed in the conflict procedure . Interestingly, both TP003 and L-838,417 are without appreciable efficacy at α1GABA A receptors, raising the possibility that α1GABA A receptors may be involved in the response rate-reducing effects of benzodiazepines.
Using previously described techniques (Licata et al. 2009 ), the present study characterized the motor-altering effects of TP003 across measures related to ataxia and myorelaxation. Studies with mutant mice implicate α1GABA A receptors in the ataxic effects of benzodiazepines and further suggest that α2GABA A and α3GABA A receptors are involved in benzodiazepine-induced myorelaxation (Rudolph et al. 1999; McKernan et al. 2000; Crestani et al. 2001) . Subsequent pharmacological studies in monkeys with subtype-selective GABA A receptor agonists agree with these earlier findings (Platt et al. 2002; Licata et al. 2005; Rowlett et al. 2005; Licata et al. 2009 ). For example, whereas both SL651498 and L-838,417 induce myorelaxant effects, neither drug was effective in producing ataxic effects in the same animals (Licata et al. 2005; Rowlett et al. 2005) . Moreover, the ataxic, but not myorelaxant, effects of benzodiazepine-type compounds were blocked by the α1GABA A -preferring antagonist, βCCT (Licata et al. 2009 ). The lack of ataxic effects observed with TP003 in the present study is consistent with the idea that α3GABA A receptors do not play a crucial role in benzodiazepine-induced ataxia. Moreover, the results presented here are consistent with the idea that the stimulation of α3GABA A receptors alone may be sufficient to produce benzodiazepine-associated myorelaxant effects.
The hyperphagic effects of benzodiazepines have been well documented (e.g., Randall et al. 1960; Cooper and Estall 1985) , with cases of night-time bingeing being of particular concern. Studies in animal models have demonstrated increases in food consumption under controlled laboratory conditions and suggest that different GABA A receptor subtypes may mediate benzodiazepine-induced hyperphagia. Further, these studies suggest that the GABA A receptor subtype mediating this effect may be species dependent. For example, α2GABA A and α3GABA A receptors are important mediators of benzodiazepine-induced hyperphagia in rodents, while α1GABA A and α5GABA A receptors do not play a role (Yerbury and Cooper 1989 , Cooper and Ridley 2005 , Stephens et al. 2005 , Morris et al. 2009 ). In contrast, an important role for α1GABA A receptors, but not α5GABA A receptors, as mediators of benzodiazepineinduced hyperphagia has been documented in primates (Wettstein and Spealman 1986 , Kumar et al. 1999 , Duke et al. 2006 ). To our knowledge, little information exists on the role of α3GABA A receptors in this effect in primates. In the present study, TP003 failed to increase the consumption of sucrose pellets at doses that engendered other behavioral effects (e.g., myorelaxant-like effects) and under conditions in which both conventional and α1GABA A -preferring agonists produce approximately 300% increases relative to baseline consumption (Duke et al. 2006 ). These observations suggest that α3GABA A receptors do not play a key role in the increases in palatable food consumption observed following conventional benzodiazepine administration and provide further evidence that the contribution of GABA A receptor subtypes in this effect may be species dependent.
Quantitative observational techniques (cf. Platt et al. 2002) were used to assess the effects of TP003 on behaviors typically associated with motor impairment and sedation, as well as vocalizations. Previous findings from our laboratory have demonstrated that conventional benzodiazepines typically have no effects on vocalizations but decrease the frequency of locomotor and environmentdirected behaviors (e.g., Platt et al. 2002; Licata et al. 2005) . Non-selective benzodiazepines also characteristically induce procumbent posture (i.e., loose-limbed, sprawled, unable to maintain an upright position), suggestive of a more pronounced, deep sedative effect (Platt et al. 2002; Licata et al. 2005; Rowlett et al. 2005; Duke et al. 2006) . In contrast to the characteristic behavioral profile associated with non-selective benzodiazepines, TP003 decreased vocalizations and rest posture with no associated increases in procumbent posture over the dose range tested. Interestingly, the behavioral profile of TP003 also differed from the previously evaluated functionally selective compounds L-838,417 and SL651498, which did not decrease vocalization, locomotion, or environment-directed behavior and did not engender rest and procumbent posture. Of particular interest is the lack of rest posture associated with SL651498, which is a full agonist at both α2GABA A and α3GABA A receptor subtypes (Licata et al. 2005) . Although clearly speculative, one intriguing possibility is that action at α2GABA A receptors (or partial agonist action at α1GABA A and/or α5GABA A receptors) attenuates the rest posture induced by selective α3GABA A stimulation. These findings collectively raise the possibility that mild, but not more pronounced, sedative effects may be induced by α3GABA A -selective agonists. An indirect support for this possibility comes from the observation that a novel α3GABA A -selective agonist (NG2-73) recently was in clinical trials for the treatment of insomnia (Wafford and Ebert 2008) .
Taken together, the data from the present set of experiments provide further evidence that the behavioral effects of benzodiazepines in primates are likely mediated by different GABA A receptors that contain distinct α subunits. Accordingly, our studies highlight several hypotheses regarding benzodiazepine action. First, our findings suggest that α3GABA A receptors play an important role in benzodiazepine-induced anxiolysis. In addition, results from the present set of experiments also implicate α3GABA A receptors in the myorelaxant and, potentially, the mild sedative effects associated with benzodiazepines. Finally, our results are consistent with the idea that the hyperphagic, ataxic, and more pronounced sedative effects of benzodiazepines require actions additional to those at α3GABA A receptors. These hypotheses should provide an important framework for studying the role of different GABA A receptor subtypes in the behavioral effects of benzodiazepine-type drugs, which in turn should help guide both the current clinical use of benzodiazepines as well as the development of improved therapeutic agents for treating anxiety and sleep disorders.
